Does Rallies show 13F holders for ARCT?

Yes. Rallies tracks hedge fund and 13F ownership data for ARCT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ARCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARCT. It does not provide personalized investment advice.

ARCT (Arcturus Therapeutics Holdings Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) is a publicly traded Healthcare sector company. As of May 21, 2026, ARCT trades at $6.76 with a market cap of $199.81M and a P/E ratio of -2.40. ARCT moved +1.94% today. Year to date, ARCT is +7.06%; over the trailing twelve months it is -46.30%. Its 52-week range spans $5.85 to $25.88. Analyst consensus is buy with an average price target of $18.50. Rallies surfaces ARCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ARCT stock?

Hedge funds tracked by Rallies that own ARCT include Panagora Asset. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arcturus Therapeutics Holdings Inc. Common Stock.

ARCT Key Metrics

Key financial metrics for ARCT
Metric	Value
Price	$6.76
Market Cap	$199.81M
P/E Ratio	-2.40
EPS	$-2.83
Dividend Yield	0.00%
52-Week High	$25.88
52-Week Low	$5.85
Volume	208
Avg Volume	0
Revenue (TTM)	$54.71M
Net Income	$-78.67M
Gross Margin	0.00%

Top Hedge Funds Holding ARCT

Panagora Asset holds 34.77K shares of ARCT, changed +0.00% as of Dec 31, 2025.

Latest ARCT News

Arcturus Extends Cash Runway to Q2 2028, Initiates 12-Week CF Study with 10mg Dose — Mar 4, 2026
Arcturus Launches 12-Week Phase 2 CF Study at 10 mg, Extends Runway to 2028 — Mar 3, 2026
Arcturus Therapeutics Faces $0.92 EPS Loss Forecast, Citi Cuts Target to $7 — Feb 26, 2026
Arcturus Outlines Inhaled mRNA CF Phase 2b Trial Plans, Secures FDA OTC Talks — Feb 11, 2026
Price Target Cut to $7; Arcturus Starts Phase 1 mRNA Flu Trial — Feb 9, 2026

Recent ARCT Insider Trades

SASSINE ANDY bought 1.24K (~$20.50K) on Aug 15, 2025.
SASSINE ANDY sold 1.24K (~$20.50K) on Aug 15, 2025.
Chivukula Pad sold 12.00K (~$249.12K) on Oct 15, 2024.

ARCT Analyst Consensus

10 analysts cover ARCT: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.50.

Common questions about ARCT

Who owns ARCT stock?: Hedge funds tracked by Rallies that own ARCT include Panagora Asset. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arcturus Therapeutics Holdings Inc. Common Stock.
Does Rallies show 13F holders for ARCT?: Yes. Rallies tracks hedge fund and 13F ownership data for ARCT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ARCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARCT. It does not provide personalized investment advice.